Skip to content

Operating Income at other companies

Avanos Medical logo
Avanos MedicalAVNS
$8.9M-13.6%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$30.9M+42.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s operating income?
Pacira BioSciences, Inc. (PCRX) reported operating income of $6.9M in Q1 2026.
How has Pacira BioSciences, Inc.'s operating income changed year-over-year?
Pacira BioSciences, Inc.'s operating income increased by 246.8% year-over-year, from $1.99M to $6.9M.
What is the long-term trend for Pacira BioSciences, Inc.'s operating income?
Over 2 years (2021 to 2025), Pacira BioSciences, Inc.'s operating income has grown at a -53.8% compound annual growth rate (CAGR), from $89.92M to $19.19M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.